10 Best Income Stocks To Invest In 2015

10 Best Income Stocks To Invest In 2015: Dendreon Corporation(DNDN)

Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of therapeutics to enhance cancer treatment options for patients. The company offers active cellular immunotherapy and small molecule product candidates to treat various cancers. Its product candidates comprise Provenge (sipuleucel-T), an active cellular immunotherapy for the treatment of metastatic, castrate-resistant prostate cancer; DN24-02, an investigational active immunotherapy for the treatment of patients with bladder, breast, ovarian, and other solid tumors expressing HER2/neu; and TRPM8, a small molecule agonist to transient receptor potential ion channel, for multiple cancers. The company also has a range of products in preclinical studies, which include Carcinoembryonic antigen for the treatment of lung, colon, and breast cancer; and Carbonic AnhydraseIX for the treatment of kidney cancer. Dendreon Corporation was founded in 1992 and is headquartered in S eattle, Washington.

Advisors' Opinion:

• [By Paul Ausick]

  Stocks on the Move: J.C. Penney Co. Inc. (NYSE: JCP) is up 8.8% at $7.39 after the CEO said he still expects positive growth in third-quarter same-store sales. Facebook Inc. (NASDAQ: FB) is down 3.3% at $50.25 as investors weigh Facebook against the pending Twitter Inc. IPO. Dendreon Corp. (NASDAQ: DNDN) is up 11.1% at $2.81 on talk of a sale of the company. Fusion-io Inc. (NYSE: FIO) is up 16.1% at $11.08 after reports of insider buying.

• [By John Udovich]

  The latest biotech news or news surrounding small cap biotech stocks like Idenix Pharmaceuticals Inc (NASDAQ: IDIX), Dendreon Corporation (NASDAQ: DNDN) and TNI BioTech, Inc (OTCMKTS: TNIB) includes a merger, a CEO resignation and a steady stream of IPO filings:

• [By Sean Williams]

  This week's winner
  Although there was no company-specific news out ofDendreon (! NASDAQ: DNDN  ) this week, following weeks of poor performance, it tacked on 8.7%. Presentations at the American Society of Clinical Oncology's annual meeting two weeks ago certainly helped to excite investors with regard to the potential of immunotherapy stocks, but Dendreon needs a lot more help than what a few early and mid-stage studies can offer. If Dendreon is to keep this rally going, it'll need decisively positive data on advanced prostate cancer treatment Provenge in Europe. We should certainly know more about its progress in Europe within the next few months.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/10-best-income-stocks-to-invest-in-2015-3.html